Oramed Pharmaceuticals
ORMP
84 hedge funds and large institutions have $80.7M invested in Oramed Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 21 increasing their positions, 19 reducing their positions, and 8 closing their positions.
263% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 8
79% more capital invested
Capital invested by funds: $45M → $80.7M (+$35.6M)
31% more funds holding
Funds holding: 64 → 84 (+20)
11% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 19
8.25% more ownership
Funds ownership: 32.74% → 40.98% (+8.2%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Mercer Global Advisors
Denver,
Colorado
|
+$7.56M |
| 2 |
BlackRock
New York
|
+$6.03M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.9M |
| 4 |
AF
Aquamarine Financial
George Town,
|
+$1.59M |
| 5 |
GIA
Gem Investment Advisors
Teaneck,
New Jersey
|
+$1.43M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BCM
BML Capital Management
Zionsville,
Indiana
|
-$9.16M |
| 2 |
Marshall Wace
London,
United Kingdom
|
-$628K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$453K |
| 4 |
RWM
Ritholtz Wealth Management
New York
|
-$283K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$227K |
ORMP Hedge Fund Activity: Q2 2026 in Review
84 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q2 2026, worth a combined $80.7M — up 79% from $45M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new ORMP positions and 8 closed out — a net gain of 21 holders — while 21 added to existing stakes and 19 trimmed.
The largest buyer was Mercer Global Advisors, adding an estimated $7.56M. The largest seller was BML Capital Management, cutting an estimated $9.16M.
- 84 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q2 2026, up from 64 in Q1 2026.
- Funds reported $80.7M of Oramed Pharmaceuticals stock for Q2 2026, up 79% quarter-over-quarter.
- 29 funds opened new Oramed Pharmaceuticals positions in Q2 2026 and 8 closed out, a net change of +21 holders.
- The largest Oramed Pharmaceuticals buyer in Q2 2026 was Mercer Global Advisors, an estimated $7.56M added.
- The largest Oramed Pharmaceuticals seller in Q2 2026 was BML Capital Management, an estimated $9.16M sold.
Based on aggregated 13F filings for Q2 2026.